12 Years and older
Male or Female
This is a Phase 2 multicenter, double-blind, randomized, placebo-controlled study assessing the efficacy and safety of lenabasum for the treatment of cystic fibrosis in patients 12 years of age or older. Approximately 415 subjects will be enrolled in this study at about 100 sites in North America, Europe, and Australia. The planned duration of treatment with study drug is 28 weeks.
Study drug will be lenabasum 20 mg BID, lenabasum 5 mg BID, and placebo in a 2:1:2 ratio.
For further information about this study or to express your interest in this study, please fill out and submit this form.
This setting allows you to view available services and providers associated with your preferred location. You can change this setting at any time.
Cookies are required to view location-specific content.
We’ve developed a new tool on our website allowing you to see content most relevant to you and your preferred location. It’s our way of making the information you need, more personalized.
You’ll find this feature labeled “Set My Location” throughout the website. Most often, you’ll see it in the top left corner of every page.
You’ll also find a feature that allows you to set your location temporarily, as seen below.